首页 | 本学科首页   官方微博 | 高级检索  
     


Clinical outcome after surgical resection of lung metastases from melanoma
Authors:Carlos Conilla  José María Gimferrer  Jordi Marruecos  Josep Domingo-Domènech  Ramón Vilella  Miquel Catalán  Josep Malvehy  Susana Puig  Teresa Castel
Affiliation:(1) Department of Radiation Oncology, Institute of Hematology and Oncology. Hospital Clínic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). University of Barcelona, Barcelona, Spain;(2) Department of Thoracic Surgery, Institute of Hematology and Oncology. Hospital Clínic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). University of Barcelona, Barcelona, Spain;(3) Department of Medical Oncology, Institute of Hematology and Oncology. Hospital Clínic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). University of Barcelona, Barcelona, Spain;(4) Department of Immunology and Dermatology, Institute of Hematology and Oncology. Hospital Clínic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). University of Barcelona, Barcelona, Spain;(5) Hospital Clínic. Dept. of Radiation Oncology, C/ Villarroel, 170, 08036 Barcelona, Spain
Abstract:Background. Surgical therapy plays an important role in the management of selected patients with metastatic melanoma. Purpose. A retrospective review of 13 patients who underwent surgical resection of lung metastases from melanoma from 1996 to 2003 was performed. The aim of the study was to analyze the clinical outcome and survival time. Materials and methods. Mean age was 45 years old (range: 31-64). Complete tumour resection was confirmed histologically. Nine patients presented one single pulmonary lesion, two lesions (n = 3) and three lesions (n = 1) but in all cases confined in the same pulmonary lobe. Results. Median survival time (MST) for the entire group was 20 months (95% confidence interval (CI): 16-24 months). The median time to disease progression after lung metastasectomy was 5 months (95% CI: 3-7 months). MST, according to the prognostic groups proposed by the International Registry of Lung Metastases, was 17 months (95% CI: 6-28 months) for group I (n = 6), MST of 20 months (95% CI: 16-24 months) for group II (n = 5) and MST of 4 months for group III (n = 2), without differences statistically significant (log-rank p = 0.423). MST regarding the time of disease free interval from diagnostic of primary tumour and lung metastases (< 36 months [n = 5] vs > 36 months [n = 8]) was 20 months and 17 months respectively, without differences statistically significant (log rank p = 0.222). Conclusions. Surgical resection when feasible provides survival rates superior to any available nonsurgical therapy. In carefully selected patients, when the resection is performed with curative intent, it may result in improved survival.
Keywords:Lung  Melanoma  Metastasis  Surgery Treatment
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号